Evidence map›Paper›PMID 37839883›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Disseminated Infection by Scedosporium/Lomentospora during Induction Therapy for Acute Myeloid Leukemia Complicated by Nontuberculous Mycobacteria.

Mari Kitahara, Masahiko Sumi, Hiroko Kazumoto, Tsutomu Shishido, Toshimitsu Ueki, Yuki Hiroshima, Katsuhiko Kamei, Hikaru Kobayashi

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. First Report ofInfection and drug resistance · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mari KitaharaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Masahiko SumiDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Hiroko KazumotoDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Tsutomu ShishidoDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Toshimitsu UekiDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Yuki HiroshimaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Katsuhiko KameiDepartment of Medical Mycology Research Center, Chiba University, Japan.
Hikaru KobayashiDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Nagano Red Cross Hospital · JPChiba University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scedosporium/Lomentospora infections are rare and are associated with a high mortality rate in immunocompromised patients. A 69-year-old man with nontuberculous mycobacteria (NTM) died during induction chemotherapy for acute myeloid leukemia because of multiple organ failure due to pneumonia. During an autopsy, Lomentospora prolificans was detected using a fungal gene analysis of the blood, lungs, spleen, kidneys, and intestines, and Scedosporium aurantiacum was detected in the lungs. NTM disease may predispose patients to Scedosporium/Lomentospora infections. Physicians should consider Scedosporium/Lomentospora spp. as an invasive fungal infection that occurs during myelosuppression, particularly when NTM is a complication.

Indexed as

Leukemia, Myeloid, AcuteMycobacterium Infections, NontuberculousScedosporiumAgedFatal OutcomeHumansImmunocompromised HostInduction ChemotherapyMaleMycosesNontuberculous Mycobacteriaacute myeloid leukemiaLomentospora prolificansnontuberculous mycobacteriaScedosporium aurantiacum

Identifiers

PMID37839883
PMCPMC11157310
OpenAlexW4387566975

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.